Last reviewed · How we verify

Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis

1 treatments

Approved treatments

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

Frequently asked questions about Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis

What drugs treat Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis?

Tracked treatments include tocilizumab or sarilumab.

What is the treatment for Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis?

Standard treatment for Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis includes tocilizumab or sarilumab. See the treatment landscape page for first-line, second-line and salvage options.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing